---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-087924"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:18:32.672151+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaccitech reports Q2 net income of $15.7M on $17.1M in Vaxzevria royalties

## Summary
- Net income $15.7M ($0.41 diluted EPS) vs $2.6M ($0.068) in Q1 2022.
- Revenue $17.1M from milestone/royalty payments from AstraZeneca for Vaxzevria sales.
- Cash $192.3M at June 30 vs $214.1M at Dec 31, 2021; $15.0M used in operations.
- R&D expenses $9.7M (down from $10.7M); G&A excluding FX gain was $8.8M.
- Clinical highlights: VTP-300 HBV data, EMA advice for MERS vaccine, HPV trial enrollment.

## SEC filing metadata
- accession: 0001104659-22-087924
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465922087924/0001104659-22-087924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465922087924/tm2222823d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-087924
- JSON: https://secwatch.observer/filing/0001104659-22-087924.json
- Plain text: https://secwatch.observer/filing/0001104659-22-087924.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.